Cargando…

Dramatic response of refractory metastatic squamous cell carcinoma of the skin with cetuximab/pembrolizumab

Cutaneous squamous cell carcinoma (cSCC) accounts for 20% of skin cancers. At an advanced stage the prognosis is poor, making cSCC the second leading cause of death from skin cancer. In cases of metastatic or unresectable disease, anti-programmed cell death 1 (anti-PD1) treatment has shown promising...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hober, Candice, Jamme, Philippe, Desmedt, Eve, Greliak, Anna, Mortier, Laurent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170330/ https://www.ncbi.nlm.nih.gov/pubmed/34104225 http://dx.doi.org/10.1177/17588359211015493

Ejemplares similares

High Response Rate to Carboplatin-Paclitaxel-Cetuximab and Pembrolizumab in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
por: Chauffert, Bruno, et al.
Publicado: (2023)

Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous Squamous Cell Carcinoma
por: Marin-Acevedo, Julian A., et al.
Publicado: (2023)

Cetuximab in Refractory Skin Cancer Treatment
por: Kalapurakal, Sini J, et al.
Publicado: (2012)

Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer
por: Han, Harry J., et al.
Publicado: (2020)

Case Report: Two Cases of Chemotherapy Refractory Metastatic Penile Squamous Cell Carcinoma With Extreme Durable Response to Pembrolizumab
por: Chahoud, Jad, et al.
Publicado: (2020)

Predictive Value of Cetuximab-Induced Skin Toxicity in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NECK
por: Uozumi, Shinya, et al.
Publicado: (2018)

Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab
por: Acero Brand, Fanny Zulay, et al.
Publicado: (2018)

Dramatic Response to First Line Single Agent Pembrolizumab in Anaplastic Thyroid Carcinoma
por: Spalart, Valérie, et al.
Publicado: (2019)

Case Report: Prolonged remission of metastatic cisplatin-refractory nasopharyngeal carcinoma with Pembrolizumab
por: Wang, Wei Cen, et al.
Publicado: (2023)

Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Report
por: Song, Haa-Na, et al.
Publicado: (2018)

Dramatic response to pembrolizumab after pseudoprogression in a patient with advanced metastatic castration‐resistant prostate cancer
por: Kageyama, Takumi, et al.
Publicado: (2022)

Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629
por: Bratland, Åse, et al.
Publicado: (2023)

Tomotherapy concomitant with cetuximab, followed by cetuximab as single-agent therapy for unresectable squamous cell carcinoma of the skin: a case report
por: Falivene, Sara, et al.
Publicado: (2014)

Cetuximab-Induced Small Intestine Stricture in Metastatic Squamous Cell Carcinoma of the Oral Cavity
por: Eisa, Mohamed, et al.
Publicado: (2022)

Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer
por: Carvalho, Adriana Camargo, et al.
Publicado: (2017)

Recurrent squamous cell carcinoma of the skin treated successfully with single agent cetuximab therapy
por: Seber, Selcuk, et al.
Publicado: (2016)

Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population
por: Chen, Wen-Chun, et al.
Publicado: (2017)

Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Taberna, Miren, et al.
Publicado: (2019)

Rescue of Immunotherapy-Refractory Metastatic Merkel Cell Carcinoma With Conventionally Fractionated Radiotherapy and Concurrent Pembrolizumab
por: Bloom, Brooke C., et al.
Publicado: (2019)

Rare case of chemotherapy-refractory metastatic vaginal squamous cell carcinoma with complete response to concurrent pembrolizumab and radiotherapy- case report and literature review
por: Ansari, Jawaher, et al.
Publicado: (2021)

A Case of Panitumumab-Responsive Metastatic Rectal Cancer Initially Refractory to Cetuximab
por: Kasagi, Yuta, et al.
Publicado: (2013)

Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre study
por: Montaudié, Henri, et al.
Publicado: (2020)

Significant response to Pembrolizumab for metastatic cutaneous squamous cell carcinoma in patient with Netherton syndrome
por: Tos, Salem M., et al.
Publicado: (2022)

Metastatic Hepatocellular Carcinoma Responsive to Pembrolizumab
por: Truong, Phu, et al.
Publicado: (2016)

Dramatic response to infliximab in refractory neurosarcoidosis
por: Chintamaneni, Sreekanth, et al.
Publicado: (2010)

The cardiotoxicity of cetuximab as single therapy in Chinese chemotherapy-refractory metastatic colorectal cancer patients
por: Tang, Xue-Miao, et al.
Publicado: (2017)

Pembrolizumab-induced pneumonitis
por: Leroy, Vincent, et al.
Publicado: (2017)

Prolonged Response to Pembrolizumab in Spindle Cell Squamous Cell Carcinoma Metastatic to the Central Nervous System
por: Liu, Yuxin, et al.
Publicado: (2019)

Pembrolizumab in relapsed or refractory Richter syndrome
por: Armand, Philippe, et al.
Publicado: (2020)

Cytokine Profiles of Head and Neck Squamous Cell Carcinoma Undergoing Dual Immunotherapy With Cetuximab and Pembrolizumab Identify Interferon Gamma-Induced Protein 10 as Novel Biomarker
por: Berszin, Michael, et al.
Publicado: (2022)

Refractory Bullous Pemphigoid in a Patient with Metastatic Lung Adenocarcinoma Treated with Pembrolizumab
por: Cardona, Andrés F., et al.
Publicado: (2021)

Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma
por: Nishimura, Nobutaka, et al.
Publicado: (2022)

Exceptional response to cetuximab monotherapy in a patient with metastatic oropharyngeal squamous cell carcinoma: a molecular insight
por: Peddi, Prakash, et al.
Publicado: (2016)

Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma
por: Chen, Tien-Hua, et al.
Publicado: (2022)

ALK-Positive Squamous Cell Carcinoma Dramatically Responded to Alectinib
por: Sagawa, Ray, et al.
Publicado: (2018)

Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck
por: Merlano, Marco, et al.
Publicado: (2007)

Cost-Effectiveness of Cetuximab for Advanced Esophageal Squamous Cell Carcinoma
por: Janmaat, Vincent T., et al.
Publicado: (2016)

Cetuximab as salvage monotherapy in chemotherapy-refractory metastatic colorectal cancer: A single-center report
por: MEKATA, EIJI, et al.
Publicado: (2013)

Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy
por: Ciardiello, Davide, et al.
Publicado: (2021)

Dramatic response to pembrolizumab with chemotherapy followed by salvage surgery in a lung cancer patient
por: Saito, Shunichi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e92t1c0cqidu8vk2jpb5cnv96q